Suppr超能文献

嗜铬细胞瘤和副神经节瘤中的血糖紊乱

Glycemic Disturbances in Pheochromocytoma and Paraganglioma.

作者信息

Ronen Joshua A, Gavin Meredith, Ruppert Misty D, Peiris Alan N

机构信息

Internal Medicine, Texas Tech University Health Sciences Center, Odessa, USA.

Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, USA.

出版信息

Cureus. 2019 Apr 27;11(4):e4551. doi: 10.7759/cureus.4551.

Abstract

In this review article, we aimed to analyze the available data on pheochromocytomas and paragangliomas as it pertains to their not as well-recognized association with significant glycemic abnormalities in the preoperative, perioperative, and postoperative settings as well as how they should be managed clinically. Pheochromocytomas are rare adrenal tumors that account for about 0.1% of hypertension. Paragangliomas, on the other hand, are even less common and have fewer clinical manifestations. Both types of tumors may have unusual modes of presentation which can challenge even the most experienced clinicians and are easy to overlook, resulting in post-mortem diagnosis. We wish to draw further attention to the life-threatening effects on glucose and insulin homeostasis that can occur in the form of hyperglycemic and hypoglycemic states. Hyperglycemia is a result of a glucose intolerant state created in the setting of catecholamine excess, which can present in the form of resistant diabetes, diabetic ketoacidosis (DKA), or even hyperglycemic hyperosmolar states (HHS). In many reported cases, these abnormalities resolve with resection of the tumor. However, past clinicians have also described a state of "reactive hypoglycemia" that can occur following tumor resection, further emphasizing the need for very close perioperative and postoperative monitoring. Severe hypoglycemia may also occur with inherited diseases linked to pheochromocytoma such as von Hippel-Lindau (VHL) disease as well as predominantly epinephrine-producing tumors, given some of the dramatic downstream effects of alpha and beta adrenoceptor agonization. While much of the data remains anecdotal, clinicians will benefit from the awareness of the protean manifestations of these tumors and the varied and lesser-known effects on glucose and insulin homeostasis.

摘要

在这篇综述文章中,我们旨在分析嗜铬细胞瘤和副神经节瘤的现有数据,这些数据涉及它们在术前、围手术期和术后与显著血糖异常之间未被充分认识的关联,以及临床上应如何对其进行管理。嗜铬细胞瘤是罕见的肾上腺肿瘤,约占高血压病例的0.1%。另一方面,副神经节瘤更为少见,临床表现也较少。这两种类型的肿瘤可能具有不寻常的表现形式,即使是经验最丰富的临床医生也可能面临挑战,且容易被忽视,从而导致死后诊断。我们希望进一步引起人们对高血糖和低血糖状态形式的、可能危及生命的对葡萄糖和胰岛素稳态影响的关注。高血糖是儿茶酚胺过量导致的葡萄糖不耐受状态的结果,可表现为难治性糖尿病、糖尿病酮症酸中毒(DKA),甚至高渗高血糖状态(HHS)。在许多报道的病例中,这些异常在肿瘤切除后得以缓解。然而,过去的临床医生也描述了肿瘤切除后可能出现的“反应性低血糖”状态,进一步强调了围手术期和术后密切监测的必要性。严重低血糖也可能发生在与嗜铬细胞瘤相关的遗传性疾病中,如冯·希佩尔-林道(VHL)病以及主要分泌肾上腺素的肿瘤,这是由于α和β肾上腺素能受体激动产生的一些显著下游效应所致。虽然许多数据仍属轶事,但临床医生将从了解这些肿瘤的多种表现形式以及对葡萄糖和胰岛素稳态的各种鲜为人知的影响中受益。

相似文献

1
Glycemic Disturbances in Pheochromocytoma and Paraganglioma.
Cureus. 2019 Apr 27;11(4):e4551. doi: 10.7759/cureus.4551.
3
Familial pheochromocytoma.
Hormones (Athens). 2009 Jan-Mar;8(1):29-38. doi: 10.14310/horm.2002.1219.
5
Diagnosis of silent pheochromocytoma and paraganglioma.
Expert Rev Endocrinol Metab. 2013 Jan;8(1):47-57. doi: 10.1586/eem.12.76.
6
Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.
Endocr Pathol. 2003 Winter;14(4):329-50. doi: 10.1385/ep:14:4:329.
7
Clinical Syndromes and Genetic Screening Strategies of Pheochromocytoma and Paraganglioma.
J Kidney Cancer VHL. 2018 Dec 27;5(4):14-22. doi: 10.15586/jkcvhl.2018.113. eCollection 2018.
8
Pheochromocytoma: a review.
Maturitas. 2014 Mar;77(3):229-38. doi: 10.1016/j.maturitas.2013.12.009. Epub 2014 Jan 5.
9
Laparoscopic excision of a familial paraganglioma.
J Laparoendosc Adv Surg Tech A. 2009 Apr;19 Suppl 1:S155-8. doi: 10.1089/lap.2008.0136.supp.

引用本文的文献

1
Diversities of Mechanism in Patients with VHL Syndrome and diabetes: A Report of Two Cases and Literature Review.
Diabetes Metab Syndr Obes. 2024 Apr 9;17:1611-1619. doi: 10.2147/DMSO.S443495. eCollection 2024.
2
Sex-Related Differences in Self-Reported Symptoms at Diagnosis in Pheochromocytomas and Paragangliomas.
J Endocr Soc. 2024 Jan 24;8(3):bvae005. doi: 10.1210/jendso/bvae005. eCollection 2024 Jan 16.
3
Secondary diabetes mellitus in pheochromocytomas and paragangliomas.
Endocrine. 2023 Dec;82(3):467-479. doi: 10.1007/s12020-023-03492-7. Epub 2023 Sep 20.
4
Challenges in Management of Concomitant Primary Aldosteronism and Pheochromocytoma.
Am J Case Rep. 2023 Jun 27;24:e939659. doi: 10.12659/AJCR.939659.
5
Predictive Factors for Catecholamine-Induced Cardiomyopathy in Patients with Pheochromocytoma and Paraganglioma.
Front Endocrinol (Lausanne). 2022 Mar 8;13:853878. doi: 10.3389/fendo.2022.853878. eCollection 2022.
6
Perioperative Management of Pheochromocytomas and Sympathetic Paragangliomas.
J Endocr Soc. 2022 Jan 14;6(2):bvac004. doi: 10.1210/jendso/bvac004. eCollection 2022 Feb 1.
8
Rare presentation of collapse and cardiomyopathy in phaeochromocytoma.
Endocrinol Diabetes Metab Case Rep. 2021 Apr 1;2021. doi: 10.1530/EDM-20-0198.
9
Persistent hypoglycemia due to an IGF-II-secreting malignant pheochromocytoma: a case report and literature review.
Clin Case Rep. 2020 Jul 23;8(12):2433-2435. doi: 10.1002/ccr3.3161. eCollection 2020 Dec.
10
Assessment of Glycometabolism Impairment and Glucose Variability Using Flash Glucose Monitoring System in Patients With Adrenal Diseases.
Front Endocrinol (Lausanne). 2020 Sep 25;11:544752. doi: 10.3389/fendo.2020.544752. eCollection 2020.

本文引用的文献

1
Case of reversible diabetes mellitus in the setting of benign Pheochromocytoma.
J Clin Transl Endocrinol Case Rep. 2018 Dec;10:1-3. doi: 10.1016/j.jecr.2018.07.003. Epub 2018 Aug 2.
2
Differences in the actions of adrenaline and noradrenaline with regard to glucose intolerance in patients with pheochromocytoma.
Endocr J. 2019 Feb 28;66(2):187-192. doi: 10.1507/endocrj.EJ18-0407. Epub 2018 Dec 13.
3
Incidence and predictive factors of hypoglycemia after pheochromocytoma resection.
Int J Urol. 2019 Feb;26(2):273-277. doi: 10.1111/iju.13864. Epub 2018 Nov 22.
5
Insulin Secretion and Insulin Sensitivity Before and After Surgical Treatment of Pheochromocytoma or Paraganglioma.
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3400-3405. doi: 10.1210/jc.2017-00357.
7
Case of Chronic Indolent Pheochromocytoma That Caused Medically Controlled Hypertension but Treatment-Resistant Diabetes Mellitus.
Hypertension. 2017 May;69(5):740-746. doi: 10.1161/HYPERTENSIONAHA.117.09183. Epub 2017 Apr 3.
8
Resection of Pheochromocytoma Improves Diabetes Mellitus in the Majority of Patients.
Ann Surg Oncol. 2017 May;24(5):1208-1213. doi: 10.1245/s10434-016-5701-6. Epub 2016 Nov 28.
9
Somatostatin-secreting Pheochromocytoma Mimicking Insulin-dependent Diabetes Mellitus.
Intern Med. 2016;55(20):2985-2991. doi: 10.2169/internalmedicine.55.7071. Epub 2016 Oct 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验